Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial by Koblin, Beryl A. et al.
Safety and Immunogenicity of an HIV Adenoviral Vector
Boost after DNA Plasmid Vaccine Prime by Route of
Administration: A Randomized Clinical Trial
Beryl A. Koblin
1*, Martin Casapia
2, Cecilia Morgan
3, Li Qin
3, Zhixue Maggie Wang
3, Olivier D. Defawe
3,
Lindsey Baden
4, Paul Goepfert
5, Georgia D. Tomaras
6, David C. Montefiori
6, M. Juliana McElrath
3, Lilian
Saavedra
2, Chuen-Yen Lau
7, Barney S. Graham
8, The NIAID HIV Vaccine Trials Network
1Laboratory of Infectious Disease Prevention, New York Blood Center, New York, New York, United States of America, 2Asociacion Civil Selva Amazonica, Iquitos, Peru,
3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 4Brigham and Women’s Hospital,
Harvard Medical School, Boston, Massachusetts, United States of America, 5Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United
States of America, 6Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America, 7Division of Clinical Research, National
Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 8Vaccine Research Center, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
Abstract
Background: In the development of HIV vaccines, improving immunogenicity while maintaining safety is critical. Route of
administration can be an important factor.
Methodology/Principal Findings: This multicenter, open-label, randomized trial, HVTN 069, compared routes of
administration on safety and immunogenicity of a DNA vaccine prime given intramuscularly at 0, 1 and 2 months and a
recombinant replication-defective adenovirus type 5 (rAd5) vaccine boost given at 6 months by intramuscular (IM),
intradermal (ID), or subcutaneous (SC) route. Randomization was computer-generated by a central data management
center; participants and staff were not blinded to group assignment. The outcomes were vaccine reactogenicity and
humoral and cellular immunogenicity. Ninety healthy, HIV-1 uninfected adults in the US and Peru, aged 18–50 were enrolled
and randomized. Due to the results of the Step Study, injections with rAd5 vaccine were halted; thus 61 received the
booster dose of rAd5 vaccine (IM: 20; ID:21; SC:20). After the rAd5 boost, significant differences by study arm were found in
severity of headache, pain and erythema/induration. Immune responses (binding and neutralizing antibodies, IFN-c ELISpot
HIV-specific responses and CD4+ and CD8+ T-cell responses by ICS) at four weeks after the rAd5 booster were not
significantly different by administration route of the rAd5 vaccine boost (Binding antibody responses: IM: 66.7%; ID: 70.0%;
SC: 77.8%; neutralizing antibody responses: IM: 11.1%; ID: 0.0%; SC 16.7%; ELISpot responses: IM: 46.7%; ID: 35.3%; SC:
44.4%; CD4+ T-cell responses: IM: 29.4%; ID: 20.0%; SC: 35.3%; CD8+ T-cell responses: IM: 29.4%; ID: 16.7%; SC: 50.0%.)
Conclusions/Significance: This study was limited by the reduced sample size. The higher frequency of local reactions after
ID and SC administration and the lack of sufficient evidence to show that there were any differences in immunogenicity by
route of administration do not support changing route of administration for the rAd5 boost.
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Introduction
While significant challenges exist in the search for a safe and
effective HIV vaccine [1], an important part of the discovery
process is testing in humans for safety and immunogenicity. In the
development of HIV vaccines, improving immunogenicity while
maintaining safety is critical. One factor that can influence safety
and immunogenicity is the route of administration. A significant
increase in immunogenicity through use of a particular route may
allow for a greater chance of demonstrated efficacy, as well as
fewer or lower doses used, which can affect the cost of vaccine
development.
Administration of vaccines into the skin or subcutaneous tissue
may be more immunogenic or provide a different pattern of
immune responses than administration by the intramuscular route.
The skin is one of the largest organs of the body and the most
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plays critical roles in both innate immunity, as a physical barrier to
pathogens, and in adaptive immunity [3]. Dermal immunization
attempts to induce an immunologically efficacious response by
providing antigen to a variety of cells, including keratinocytes and
dendritic cells (DC). After maturation, Langerhans cells (dendritic
cells found mainly in the epidermis) and dermal DC (found
mainly in the dermis) can migrate to draining lymph nodes
where presentation of antigens to T cells can initiate a variety of
immunological responses [4,5]. In contrast, intramuscular vacci-
nation delivers antigen to a place with fewer professional antigen-
presenting cells [6,7]. Thus, it is possible that different routes of
administration may produce differences in T-cell memory or
effector populations and drive differences in trafficking patterns of
lymphocytes responding to HIV vaccines. Furthermore, dermal
immunization may provide an advantage over intramuscular
immunization if lower doses of the vaccine can be utilized with
similar or improved immune responses. Finally, dermal immuni-
zation could more effectively overcome any dampening effects of
pre-existing immunity to vaccine vectors.
Studies of a variety of vaccines have found that intradermal
vaccination can be just as effective as, or more effective than,
intramuscular vaccination, using doses several fold lower [7–12]
but this advantage may be influenced by other factors, such as age
of the host. Subcutaneous dosing has been found to be comparable
to intramuscular dosing in terms of immunogenicity [10,11]. In
many of these studies, the frequency of local reactions to vaccines
given by the intradermal or subcutaneous route were higher than
when given intramuscularly, but usually mild and transient. There
have been no overall differences in systemic reactions or serious
adverse events [7–11,13–15].
Using vaccines with demonstrated immunogenicity in multiple
clinical trials [16–18], the objective of this studywas to compare
the effect of routes of administration on safety and immunogenic-
ity of a prime-boost regimen of two HIV vaccines: a DNA vaccine
prime given intramuscularly via the needle-free BiojectorH and a
recombinant replication-defective adenovirus type 5 vaccine boost
given one of three routes: intramuscularly, intradermally, or
subcutaneously (HIV Vaccine Trials Network (HVTN) Protocol
# 069).
Methods
Study design and procedures
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S2. The study was designed as a multicenter, open label,
randomized trial. Starting in November 2006, 90 participants
were randomized to one of three groups designated by the route of
administration of the rAd5 vaccine (30 participants in each group).
The randomization was stratified by country (United States and
Peru) using a fixed block size of 6 to ensure balance across arms.
Assignment to group was via a web-based randomization system
managed by the central data management center. Participants
and site staff were not blinded as to the group assignment.
Randomization was not stratified by Ad5 neutralizing antibody
titer. DNA vaccine injections were planned to be given at months
0, 1, and 2 months and rAd5 vaccine at 6 months. Follow-up visits
were conducted two weeks after each injection and at 7, 9 and 12
months post-enrollment.
Local and systemic reactogenicity assessments were performed
following each vaccination for up to 3 days and were graded as
mild (transient or minimal symptoms), moderate (symptoms requi-
ring modification of activity), severe (incapacitating symptoms
resulting in bed rest and/or loss of work or social activities) or life-
threatening. Any adverse events were reported for the entire study
duration for individual participants and coded for their relationship
to study product (not, possibly, probably or definitely related).
In September 2007, the Step Study involving the MRKAd5
HIV-1 gag/pol/nef vaccine was stopped due to futility since the
results to date indicated that the vaccine did not prevent HIV-1
infection nor reduce early viral level [19]. Furthermore, there
seemed to be an increase risk of HIV infection among male
vaccinees who had prior neutralizing antibodies against adenovi-
rus type 5. Based on this observation, in October 2007, leadership
of the HVTN 069 protocol, HVTN and Division of AIDS
(DAIDS) decided to halt all injections of the rAd5 vaccine in this
protocol.
Study participants
After written informed consent, participants were screened for
eligibility and willingness to participate at five HVTN sites in the
United States and Peru: Birmingham, AL; Boston, MA; New
York, NY; Seattle, WA; Iquitos, Peru. Potential participants were
drawn from a large pool of participants screening at the study sites
for multiple HVTN vaccine clinical trials. Based on laboratory
tests, medical history, physical examinations and interview
questions, healthy, HIV-1-uninfected adults, aged 18–50 years
were enrolled. In some studies, preexisting immunity to adenovirus
serotype 5 (Ad5) has been found to decrease immune responses to
recombinant adenoviral serotype 5 vaccines [16,20]. On the other
hand, in regions of the world most affected by HIV, 75–99% of
populations are seropositive for Ad5 neutralizing antibodies [21].
Thus, to more closely reflect the situation in many areas of the
world, only volunteers possessing detectable levels of neutralizing
antibodies against Ad5 (titer $1:12) were enrolled. All participants
were counseled about HIV risk reduction and pregnancy
prevention and assessed about potential social impacts at each
study visit.
Ethics
The study protocol was approved by the institutional review
boards of all participating study sites: University of Alabama at
Birmingham IRB for the Birmingham, AL site; Partners Human
Research Committee for the Boston, MA site; New York Blood
Center IRB and Columbia University Medical Center IRB for the
New York City, NY sites; Fred Hutchinson Cancer Research
Center IRB for the Seattle, WA site and Comite ´ Institucional de
Bioe ´tica, Asociacio ´n Civil Impacta for the Iquitos, Peru site. All
study participants provided written informed consent prior to
participation. The HVTN Safety Monitoring Board reviewed the
study approximately every 4 months.
Vaccines
The DNA vaccine (VRC-HIVDNA009-00-VP) was composed
of 4 closed, circular DNA plasmids. One plasmid was designed to
express clade B HIV-1 Gag/Pol/Nef polyprotein. The other 3
plasmids were designed to express HIV-1 Env glycoprotein from
clade A, clade B, and clade C. The recombinant adenoviral vector
product (VRC-HIVADV014-00-VP) (rAd5) was a replication
defective, combination vaccine containing a mixture of 4 recom-
binant serotype 5 adenoviral vectors. Each vector expresses 1 of
the 4 HIV antigens—clade B GagPol polyprotein, clade A Env,
clade B Env, and clade C Env—in a 3:1:1:1 ratio.
The vaccines were administered in a prime-boost combination
with 4 mg of the DNA vaccine prime administered intramuscu-
larly (IM) as one 1 ml injection via the needle-free BiojectorH. The
boost rAd5 vaccine was administered in one of three ways: one
Administration Route of HIV rAd5 Vaccine
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10 PU intramuscular (IM), one 0.1 ml
injection of 1610
11 PU intradermal (ID), or one 1 ml injection of
1610
10 PU subcutaneous (SC).
Humoral assays
Binding antibodies by ELISA. Anti-Gag and Anti-Env
binding antibody responses were determined by validated
ELISAs. Sera from cryopreserved samples were tested in
duplicate in microtiter plates (NUNC) coated with gp140 Env
protein (Con S gp140, a group M consensus, provided by Drs.
Liao and Haynes, Duke University). Sera were diluted and
incubated with the antigens bound to the plate. The plates were
washed with an automated and calibrated plate washer (Bio-Tek).
Response was considered positive if the difference in duplicate
antigen-containing and non-antigen-containing wells (OD antigen
– OD non-antigen) had an optical density (OD) greater than or
equal to an OD of 0.2 with background subtracted and the OD
was $3 times the baseline OD (M2 plate reader, Molecular
Devices). Standard curves were generated from the plot of
absorbance (450) against the log of serum dilution and sigmoidal
curves were fit using a four-parameter logistic equation (Softmax
Pro) [22,23].
Neutralization assay. Neutralization was measured as a
function of reductions in luciferase reporter gene expression after a
single round of infection in TZM-bl cells as described [24,25].
TZM-bl cells were obtained from the NIH AIDS Research and
Reference Reagent Program, as contributed by John Kappes and
Xiaoyun Wu. Briefly, 200 TCID50 of virus was incubated with
serial 3-fold dilutions of test sample in duplicate in a total volume
of 150 ml for 1 hr at 37uC in 96-well flat-bottom culture plates.
Freshly trypsinized cells (10,000 cells in 100 ml of growth medium
containing 75 mg/ml DEAE dextran) were added to each well.
One set of control wells received cells + virus (virus control) and
another set received cells only (background control). After a
48 hour incubation, 100 ml of cells was transferred to a 96-well
black solid plates (Costar) for measurements of luminescence
using the Britelite Luminescence Reporter Gene Assay System
(PerkinElmer Life Sciences). Neutralization titers were the dilution
at which relative luminescence units (RLU) were reduced by 50%
compared to virus control wells after subtraction of background
RLUs. Response to an isolate was considered positive if the titer
was $25. An assay stock of uncloned HIV-1 MN was produced in
H9 cells and titrated in TZM-bl cells. Assay stocks of molecularly
cloned Bal.26 (clade B, tier 1A), 92RW020.2 (clade A, tier 2) and
97ZA012.29 (clade C, tier 2), all matched to the vaccine strains
and used as Env-pseudotyped viruses were prepared by
transfection in 293T cells and were titrated in TZM-bl cells as
described [25].
End of study diagnostic EIA testing. At the last study visit,
participants were screened by commercial EIA (Abbot Laboratories
HIV-1/HIV-2 rDNA, Biorad Genetic Systems HIV-1/HIV-2 Plus
O and Biorad Genetic Systems rLAV EIA).
Cellular assays
IFN-c ELISpot assays. Validated IFN-c ELISpot assays [26]
were conducted using previously cryopreserved PBMC stimulated
ex vivo with pools of peptides 15 amino acids in length at a final
concentration of 1 mg/ml. The peptide sequences were designed to
incorporate the most frequent HIV 10mers from the Los Alamos
National Laboratory online database (http://www.hiv.lanl.gov/
content/sequence/HIV/mainpage.html).Nine global PTE (potential
T-cell epitope) peptide pools encompassing 1407 total peptides (three
pools for Pol PTE and Env PTE, two pools for Gag PTE and one
pool for Nef PTE peptides) were used [27]. PBMC incubated with
media alone were used in the negative control wells, and PBMC
treated with PHA were used in the positive control wells. Responses
were measured as the number ofspot-forming cellsper million (SFC/
10
6) PBMC and expressed as geometric means; the criteria for
positive and negative responses were defined as previously described
[28].
Intracellular cytokine staining (ICS) assays. Intracellular
cytokine staining (ICS) assays were performed by flow cytometry
using previously cryopreserved PBMC to determine both HIV-
specific CD4+ and CD8+ T-cell responses [29]. In summary,
thawed PBMC were incubated overnight and then stimulated for
six hours with HIV-1 peptide pools in the presence of Brefeldin A
(Sigma, St. Louis, MO) and 1 mg/ml each of 2CD28 and CD49d
antibodies (BD Biosciences, San Jose, CA). The pools of HIV
peptides were 15 amino acids in length and used at a final
concentration of 1 mg/ml. The peptide sequences were designed
as described above. Duplicate wells of PBMC incubated with
DMSO were used as the negative control, and SEB (Sigma, St.
Louis, MO) stimulation was used as the positive control. A
previously validated 8-color ICS protocol was used to detect live
IFN-c- and IL-2-secreting CD3+/CD8+ and CD3+/CD4+ HIV-
specific T cells. For the flow cytometric analysis, the specimens
were collected from 96-well plates using the High Throughput
Sampler (HTS, BD) device on a BD LSRII and then analyzed
using FlowJo software (Treestar, Inc; OR) and LabKey Flow [30].
Positive responses and criteria for evaluable responses were
determined as previously described [29] and were based on
background measurements and the number of T cells examined.
Since separate criteria are applied for CD4+ and CD8+ cells, the
total number of specimens included in each ICS analysis can differ
between the CD4+ and CD8+ T-cell evaluations.
Statistical analysis
The primary goal was to determine if ID or SC route of
administration of the rAd5 boost was superior to IM administra-
tion in eliciting vaccine-induced HIV-specific T cell responses at
four weeks after the rAd5 boost. Because IM administration is the
most common method to administer these products, IM
administration would continue to be used with this product unless
there is a large improvement in immune response.
Sample size. The original design of 30 participants per group
had 82% power to detect a 2-fold difference in mean response
magnitudes between two groups for a two-sided two-sample t-test
with a Type I error rate of 0.05. Due to the suspension of rAd5
vaccinations, the sample size was reduced (61 of 90 enrolled
participants) and data were instead analyzed per protocol using
overall tests to determine if there were any differences among the
three routes of administration. If any significant differences were
found, then pair-wise comparisons were conducted and p-values
adjusted accordingly.
Safety assessments. Safety data from enrolled participants
were analyzed according to initial randomization assignment.
For reactogenicity, the number and percentage of participants
experiencing each type of reactogenicity sign or symptom was
tabulated by severity. For a given sign or symptom, each
participant’s reactogenicity was counted once under the maxi-
mum severity after each injection. Kruskall-Wallis test was used for
testing overall difference in terms of severity of symptoms by
treatment group for each sign or symptom separately. When
there was a significant overall difference, pairwise compari-
sons (IM vs ID, IM vs SC and ID vs SC) were performed
and Bonferroni multiplicity adjustment was applied. Adverse
experiences were tabulated using MedDRA preferred terms. The
number and percentage of participants experiencing each specific
Administration Route of HIV rAd5 Vaccine
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to treatment. Each participant’s adverse experience was counted
once under the maximum severity or the strongest recorded causal
relationship to study product. Boxplots of local laboratory values
were generated for baseline values and for values measured during
the course of the study to present the distribution of these data.
Kruskal-Wallis test was used to test for differences in terms of
severity of adverse events by treatment group.
Immunogenicity. Fisher exact test was conducted to
compare if the response rates among the three routes of
administration differed within each assay. For the comparison of
magnitudes of responses, the non-parametric Kruskal-Wallis test
was performed to determine if there were any overall differences
among the three routes.
Results
Enrollment and follow-up
Between November 2006 and October 2007, 90 participants
were enrolled and randomized to one of the three study groups at
sites in the US and Peru. The median age of participants was 27.0
years; 41% were women, 40% were non-Hispanic Whites, 32%
were Hispanic and 18% non-Hispanic Black (Table 1). There were
no significant differences in gender, race/ethnicity or age by study
group. All participants received the first dose of DNA vaccine, 88
(99%) received the second dose of DNA vaccine, 84 (93%)
received the third dose of DNA vaccine and 61 (68%) received the
booster dose of rAd5 vaccine. Of the 29 missing the rAd5 booster
dose (IM: 10, ID: 9, SC: 10), 22 (75.9%) were due to the
suspension of vaccination after the Step Study results were
released. Of the remaining 7 participants, 3 missed due to inability
to schedule vaccination within the target window, 1 due to receipt
of yellow fever vaccine (ID group) and 1 due to military enlistment
(SC group). One discontinued vaccination after 2 DNA doses due
to hypoesthesia which was deemed to be mild and probably not
related to study vaccine (ID group). The numbness resolved within
20 days and the study participant declined further injections. The
final participant discontinued vaccination due to a decrease in
hemoglobin levels after only one dose of DNA vaccine (SC group).
The decrease was deemed as mild and not related to study product
but the study safety team decided to discontinue vaccination.
Hemoglobulin levels returned to baseline values within 22 days.
Retention at the last study visit at 12 months was 94% (Figure 1).
Vaccine Safety
Overall, the vaccines were well-tolerated. Systemic reactoge-
nicity, including malaise, myalgia, headache, nausea, vomiting,
chills and arthralgia was generally mild, with 39% of participants
reporting no systemic symptoms and 34% reporting mild
symptoms. After the three DNA doses, there were no significant
differences in local or systemic reactogenicity by study arm. In
contrast, after the rAd5 boost, significant differences by study arm
were found in severity of headache (p=0.01), pain (p=0.04) and
erythema and/or induration (p,0.0001) (Table 2). Pairwise
comparisons found significantly more severe headaches and pain
in the SC group compared to the ID group (adjusted p=0.0167
for both). Erythema and/or induration was significantly more
severe in the ID group compared to IM group (adjusted
Table 1. Demographic characteristics and vaccination by study arm.
Study group
Total
(n=90)
DNA+ rAd5 IM
(n=30)
DNA+ rAd5 ID
(n=30)
DNA+ rAd5 SC
(n=30)
Characteristic N (%) N (%) N (%) N (%)
Gender
Male 53 (59) 17 (57) 16 (53) 20 (67)
Female 37 (41) 13 (43) 14 (47) 10 (33)
Race/ethnicity
White-non Hispanic 36 (40) 9 (30) 11 (37) 16 (53)
Hispanic 29 (32) 10 (33) 9 (30) 10 (33)
Black-non Hispanic 16 (18) 8 (27) 7 (23) 1 (3)
Asian 4 (4) 0 (0) 1 (3) 3 (10)
Native American/Alaskan Native 1 (1) 1 (3) 0 (0) 0 (0)
Multiracial 4 (4) 2 (7) 2 (7) 0 (0)
Age
18–20 16 (18) 7 (23) 5 (17) 4 (13)
21–30 41 (46) 15 (50) 10 (33) 16 (53)
31–40 14 (16) 3 (10) 5 (17) 6 (20)
41–50 19 (21) 5 (17) 10 (33) 4 (13)
Vaccinations
Day 0 90 (100) 30 (100) 30 (100) 30 (100)
Day 28 88 (98) 30 (100) 30 (100) 28 (93)
Day 56 84 (93) 29 (97) 27 (90) 28 (93)
Day 168 61 (68) 20 (67) 21 (70) 20 (67)
doi:10.1371/journal.pone.0024517.t001
Administration Route of HIV rAd5 Vaccine
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(adjusted p=0.0167).
Two participants reported severe symptoms. One participant in
the IM group reported severe malaise and chills on Day 1 after the
rAd5 boost which resolved by Day 2. The other participant in the
ID group reported severe malaise on Day 2 after the last DNA
dose which became mild by Day 3. There were no significant
differences in reporting of any systemic reactogenicity or
laboratory values by study arm.
Adverse events were reported by 83 (92.2%) of participants; 80
of those participants experienced mild or moderate events. Two
participants had severe adverse events (one with abnormal weight
loss and one with alanine aminotransferase increase) and one with
a life-threatening event (malaria and fetal loss). None of these
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0024517.g001
Table 2. Reactogenicity after rAd5 boost by study group.
Study group
Total DNA+ rAd5 IM DNA+ rAd5 ID DNA+ rAd5 SC
+/n (%) +/n (%) +/n (%) +/n (%)
Headache
None 51/61 (83.6) 17/20 (85.0) 21/21 (100.0) 13/20 (65.0)
Mild 6/61 (9.8) 0/20 (0.0) 0/21 (0.0) 6/20 (30.0)
Moderate 4/61 (6.6) 3/20 (15.0) 0/21 (0.0) 1/20 (5.0)
Pain
None 33/61 (54.1) 11/20 (55.0) 15/21 (71.4) 7/20 (35.0)
Mild 21/61 (34.4) 6/20 (30.0) 6/21 (28.6) 9/20 (45.0)
Moderate 6/61 (9.8) 2/20 (10.0) 0/21 (0.0) 4/20 (20.0)
Severe 1/61 (1.6) 1/20 (5.0) 0/21 (0.0) 0/20 (0.0)
Erythema/induration
None 24/61 (39.3) 18/20 (90.0) 1/21 (4.8) 5/20 (25.0)
.0t o2 5c m
2 28/61 (45.9) 2/20 (10.0) 19/21 (90.5) 7/20 (35.0)
.25 to 81 cm
2 6/61 (9.8) 0/20 (0.0) 1/21 (4.8) 5/20 (25.0)
.81 cm
2 3/61 (4.9) 0/20 (0.0) 0/21 (0.0) 3/20 (15.0)
doi:10.1371/journal.pone.0024517.t002
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There were no significant differences in severity of adverse events
by study arm (p=0.60).
Immunogenicity
Humoral responses. Binding antibodies by ELISA at four
weeks after the rAd5 boost are reported for 56 (91.8%) of the 61
participants who received the rAd5 boost (18 in the IM group, 20
in the ID group and 18 in the SC group). Five participants were
not included in the analysis (IM=2, ID=1, and SC=2) since
their study visits occurred outside of the target windows. The
response rates in the three study arms were 66.7% (12/18; 95%
CI: 43.7, 83.7) for the IM group, 70.0% (14/20; 95% CI:
48.1,85.5) for the ID group, and 77.8% (14/18; 95% CI: 54.8,
91.0) for the SC group and were not statistically different. The
medians of optical density for positive responders were 1.19 for the
IM group, 0.93 for the ID group and 0.72 for the SC group
(Figure 2).
Neutralizing antibodies were examined at four weeks after the
rAd5 boost for 56 (91.8%) of the 61 participants (18 in the IM
group, 20 in the ID group and 18 in the SC group). Five
participants (IM=2, ID=1 and SC=2) were not included due to
visits occurring outside the target window. For the MN isolate,
participants in the SC group had the highest proportion of positive
responses, 16.7% (3/18; 95% CI: 5.8, 39.2), followed by the IM
group with 11.1% (2/18; 95% CI: 3.1, 32.8) and no response in
the ID group (0/20: 95% CI:0.0, 16.1). These differences were not
statistically significant (p=0.18). No positive responses were found
to other isolates.
Among the 61 participants who received the rAd5 boost, 53
(86.9%) tested serologically positive at the end of study using the
Abbot test kit; 75.0% (15/20; 95% CI: 53.1, 88.8) for the IM
group, 90.5% (19/21; 95% CI: 71.1, 97.3) for the ID group and
95.0% (19/20; 95% CI: 76.4, 99.1) for the SC group. A lower
percent (45.9%) were positive by BioRad Genetic Systems rLAV;
65.0% (13/20; 95% CI: 43.3, 81.9) for the IM group, 33.3% (7/
21; 95% CI: 17.2, 54.6) for the ID group and 40.0% (8/20; 95%
CI: 21.9, 61.3) for the SC group. Only 1 participant (ID group)
had a positive test by the BioRad Genetic Systems HIV1/2 plus O
kit.
Cellular responses. Vaccine-induced HIV-1 specific T-cell
responses were measured at 2 weeks after the third DNA
vaccination and 4 weeks after the rAd5 vaccine boost. IFN-c
ELISpot assays were completed on 57 participants at two weeks
after the third DNA dose and on 51 at four weeks after the rAd5
boost.
The frequency of IFN-c ELISpot HIV-specific responses after
the DNA immunization was 42.1% and after the rAd5 vaccine
boost was 41.2% (Table 3). There were no significant differences
(p=0.82) in the percent responding at 4 week post rAd5 boost by
study group: 46.7% in the IM group (7/15; 95% CI: 24.8, 69.9),
35.3% in the ID group (6/17; 95% CI: 17.3, 58.7) and 44.4% in
the SC group (8/18; 95% CI: 24.6, 66.3). The specificity of the
ELISpot responses was heavily biased towards Env. Figure 3
provides the boxplots of IFN-c HIV-specific responses by study
visit and study arm for each of the antigens (Env, Gag, Nef and
Pol). The median magnitude of Env-specific responses in the 24
positive responders post DNA priming was 116 SFC/10
6 PBMCs
(range: 66–418) and 177 SFC/10
6 PBMCs (range: 62–2204) in the
21 positive responders after rAd5 boost. There was no significant
difference in ELISpot magnitude based on delivery route (Env:
p=0.40; Gag: p=0.11; Nef: p=0.17; Pol: p=0.10).
For the ICS assay, CD4+ T-cell responses are reported on 54
(88.5%) of the 61 participants at two weeks after the third DNA
dose and 49 (80.3%) at four weeks after the rAd5 boost. HIV-1-
specific response rates for CD4+ T-cells expressing IL-2 and/or
IFN-c using the ICS assay were found to be lower after rAd5
boosting compared to response rates after initial DNA priming
(Table 4). Response rates at 4 weeks post rAd5 boost were not
significantly different (p=0.67) by study arm: 29.4% in the IM
group (5/17; 95% CI: 13.3, 53.1), 20.0% in the ID group (3/15;
95% CI: 7.0, 45.2) and 35.3% in the SC group (6/17; 95% CI:
17.3, 58.7). Env was most frequently recognized after DNA
priming and after rAd5 boosting, responses broadened somewhat
to include Gag (Figure 4).
For CD8+ T-cell responses, response rates are reported for 57
(93.4%) participants at two weeks after the third DNA dose and 53
(86.9%) at four weeks after the rAd5 boost. CD8+ T-cell responses
were more frequent after rAd5 boosting (Table 3). Response rates
at 4 weeks post rAd5 boost were not significantly different
(p=0.11) by study arm: 29.4% in the IM group (5/17; 95% CI:
13.3, 53.1), 16.7% in the ID group (3/18; 95% CI: 5.8, 39.2) and
50.0% in the SC group (9/18; 95% CI: 29.0, 71.0). Most responses
were to Env and after the rAd5 boosting, responses broaden to
include Pol with a few responses to Gag (Figure 5).
Discussion
This study was designed to determine the effect of route of
administration of a boost on safety and immunogenicity of a prime-
boost regimen of two HIV vaccines in Ad5-seropositive volunteers.
The main limitation of this study is the reduction of sample size, and
thus limited power, due to the discontinuance of vaccinations after
the results of the Step Study were available. rAd5 immunizations
were resumed only in studies that excluded participants who were
found to have pre-existing immunity to Ad5, and a DNA prime-
rAd5 boost regimen is now being tested in an efficacy trial among
Ad5 seronegative participants [31]. Resuming vaccination with
rAd5 was not implemented in this protocol.
Overall, the vaccines were found to be well tolerated, adding to
the overall safety profile of these vaccines [18,32–34]. A greater
frequency and level of severity of erythema and induration were
observed among those receiving rAd5 vaccine by the ID and SC
routes compared to the IM route. This finding is consistent with
Figure 2. Anti-Env Binding antibody response by administra-
tion route at 4 weeks post Ad5 boost. Anti-Env binding antibody
levels and % response are shown per route of administration. Positive
responses are in red and non-responders in blue.
doi:10.1371/journal.pone.0024517.g002
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including influenza, hepatitis A and B, modified vaccinia Ankara,
and anthrax [7–11,13,15].
Varying the route of administration of the rAd5 boost to increase
immunogenicity was of particular interest since pre-existing
immunity to adenovirus type 5 has been shown to diminish the
immune response to rAd5 vaccines [35,36]. Given higher rates of
some reactogenicity and not sufficient evidence to show that there is
a difference by route of administration, adopting a SC or ID route
would likely not aid in addressing prior Ad5 immunity.
Table 3. ELISpot response rates to any HIV peptide by study visit and study group.
Study group
Total DNA+ rAd5 IM DNA+ rAd5 ID DNA+ rAd5 SC
+/n (%) +/n (%) +/n (%) +/n (%)
Baseline 2/58 (3.4) 1/19 (5.3) 0/18 (0.0) 1/20 (5.0)
2 weeks post DNA series 24/57 (42.1) 8/18 (44.4) 10/20 (50.0) 6/19 (31.6)
4 weeks post rAd5 boost 21/51 (41.2) 7/15 (46.7) 6/17 (35.3) 8/18 (44.4)
doi:10.1371/journal.pone.0024517.t003
Figure 3. Interferon-c ELISpot response to Env, Gag, Nef, Pol global PTE peptide stimulation by administration route. (A) At 2 weeks
post last DNA prime and (B) 4 weeks post Ad5 boost. The scale indicates spot-forming cells per million peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0024517.g003
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reported for other candidate HIV vaccines. Bansal et al [37]
compared prime vaccination with a DNA vaccine delivered by ID
and IM route, boosted by a protein vaccine delivered by IM. They
found that the ID group had the lowest magnitude of Env-specific
CD4 T-cell responses after the DNA prime but there were no
Table 4. ICS responses to any HIV antigen by study visit and study group.
Study group
Total DNA+ rAd5 IM DNA+ rAd5 ID DNA+ rAd5 SC
+/n % +/n (%) +/n (%) +/n (%)
CD4+ T cell responses
2 weeks post DNA series 22/54 (40.7) 6/17 (35.3) 8/19 (42.1) 8/19 (42.1)
4 weeks post Ad5 boost 14/49 (28.6) 5/17 (29.4) 3/15 (20.0) 6/17 (35.3)
CD8+ T cell responses
2 weeks post DNA series 11/57 (16.9) 4/19 (21.1) 2/20 (10.0) 5/19 (26.3)
4 weeks post Ad5 boost 15/53 (32.0) 5/17 (29.4) 3/18 (16.7) 9/18 (50.0)
doi:10.1371/journal.pone.0024517.t004
Figure 4. Percentage of CD4+ T cells producing interferon c and/or Interleukine 2 by administration route. (A) in response to any Env
peptides (B) in response to any Gag peptides before (2 weeks post last DNA prime) and after the Ad5 boost (4 weeks post Ad5 boost).
doi:10.1371/journal.pone.0024517.g004
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IM route of an HIV-lipopeptide candidate vaccine and found that
while more local reactions were observed with the ID route of
administration, HIV-specific CD8+ T-cell responses were similar
between groups [38].
The effect of administration route was tested in this study using
vaccines with demonstrated immunogenicity in multiple clinical
trials [17,18,39]. In one study among participants in the United
States, of whom only a minority had pre-existing immunity to Ad5
in contrast to this study, the DNA prime (using either 4- or 6-
plasmid vaccines) combined with rAd5 boost was more highly
immunogenic than observed in this study [18]. Another study using
the 4-plasmid DNA and rAd5 vaccines used in the current study
found a somewhat higher frequency of IFN-c ELISpot responses
(58% vs. 41%) and higher CD8+ T-cell response rates (44% vs.
32%) but lower CD4+ T-cell response rates (17% vs 29%) [40].
However, many of the participants had no pre-existing Ad5
immunity. In studies using the 6-plasmid DNA priming, HIV-
specific T cell responses were found at slightly lower frequencies
among participants with pre-existing Ad5 immunity in studies
conducted in East Africa [32,33]. In this study utilizing the 4-
plasmid DNA for priming in participants who were exclusively Ad5
seropositive, the relatively low T-cell response was not unexpected.
A high frequency of HIV-specific antibody responses was seen,
validating the immunogenicity and stability of the product.
In summary, limited by the reduced sample size, this study does
not provide sufficient evidence to show that there were any
differences in immunogenicity by route of administration. With a
higher frequency of headache, pain and erythema and/or
induration after ID and SC administration, this study does not
support changing route of administration for the rAd5 boost.
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Figure 5. Percentage of CD8+ T cells producing interferon c and/or Interleukine 2 by administration route. (A) in response to any Env
peptides (B) in response to any Pol peptides before (2 weeks post last DNA prime) and after the Ad5 boost (4 weeks post Ad5 boost).
doi:10.1371/journal.pone.0024517.g005
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